Breaking
Novo Nordisk Launches Wegovy in China Before Eli Lilly, Capturing World's Largest Obesity MarketVanda Pharmaceuticals Launches NEREUS (Tradipitant) - First New Motion Sickness Drug in 40+ Years Now AvailableTakeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency Disease
🇺🇸 FDA

HIV Treatment

Page 1 • 2 items

Global HIV treatment market intelligence: Stay ahead with insights on drug development, regulatory approvals, and investment opportunities.

FDA Grants Priority Review for Gilead's Bictegravir Plus Lenacapavir HIV Treatment Combination
NewsHIV TreatmentApr 29, 2026

FDA Grants Priority Review for Gilead's Bictegravir Plus Lenacapavir HIV Treatment Combination

Gilead Sciences receives FDA priority review for novel once-daily HIV treatment combining bictegravir and lenacapavir, potentially the smallest single-tablet regimen.

James Chen, PharmD
FDA Approves Merck's IDVYNSO: First Non-INSTI, Tenofovir-Free Two-Drug HIV Treatment
NewsHIV TreatmentApr 22, 2026

FDA Approves Merck's IDVYNSO: First Non-INSTI, Tenofovir-Free Two-Drug HIV Treatment

FDA approves Merck's IDVYNSO (doravirine/islatravir), the first non-INSTI, tenofovir-free two-drug HIV regimen showing non-inferior efficacy to BIKTARVY.

James Chen, PharmD